论文部分内容阅读
目的:观察诺和灵30R与二甲双胍联合应用治疗单独应用诺和灵30R不达标的2型糖尿病患者的临床效果。方法:选择在本院单独接受诺和灵30R治疗2周后血糖控制不达标的2型糖尿病患者49例,给予二甲双胍联合治疗,比较治疗前后的FBG(空腹血糖)、PBG(餐后2小时血糖)及HbA1c(糖化血红蛋白)水平。结果:治疗8周后FBG、PBG下降显著(P<0.01),HbA1c下降明显(P<0.05),平均每天诺和灵30R用量,相比治疗前减少18%。结论:诺和灵30R联合应用二甲双胍治疗2型糖尿病可以有效的控制空腹及餐后血糖,并可以增强胰岛素敏感性,减少胰岛素用量,二者联用有协同的作用。
OBJECTIVE: To observe the clinical effect of combined noradren 30R and metformin in the treatment of type 2 diabetes patients who did not meet the standard of Norogen 30R alone. Methods: Forty-nine patients with type 2 diabetes who did not receive blood glucose control 2 weeks after receiving Noropen 30R alone were given metformin combination therapy. FBG (fasting plasma glucose), PBG (2-hour postprandial blood glucose ) And HbA1c (HbA1c) levels. Results: After 8 weeks of treatment, FBG and PBG decreased significantly (P <0.01) and HbA1c decreased significantly (P <0.05). The mean daily dose of Novolin 30R decreased 18% compared with that before treatment. Conclusion: Novolin 30R combined with metformin in the treatment of type 2 diabetes can effectively control fasting and postprandial blood glucose, and can enhance insulin sensitivity, reduce insulin dosage, the two combined with a synergistic effect.